Navigation Links
Misonix Reports First Quarter Fiscal 2011 Financial Results
Date:11/12/2010

FARMINGDALE, N.Y., Nov. 12, 2010 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of state of the art, ultrasonic medical device technology, which worldwide is used for acute health conditions, today reported financial results for the first fiscal quarter ending September 30, 2010.  Michael A. McManus, Jr., President and Chief Executive Officer, and Richard Zaremba, Senior VP and Chief Financial Officer, will host a conference call Monday, November 15, 2010 at 4:30 pm to discuss the Company's first fiscal quarter results.

The Company also reported the following financial and operational achievements:

  • A 24% increase in revenue for the first fiscal quarter 2011 compared with the first fiscal quarter 2010
  • Medical device products revenue for the first fiscal quarter 2011 increased 34% to $2.7 million compared with the first fiscal quarter 2010
  • Gross profit as a percentage of revenues increased to 50.3% in the first fiscal quarter 2011

  • Revenues for the three months ended September 30, 2010 were $3.3 million, a 24% increase when compared with $2.6 million for the same period in fiscal 2010.  Medical device product sales increased $689,000 or 34% to $2.7 million and laboratory and scientific product sales decreased $62,000 to $566,000 for the three months ended September 30, 2010.  The increase in revenue for medical device products during the three months ended September 30, 2010 was primarily attributable to sales of the Company's BoneScalpel™, Neuroaspirator, AutoSonix™ and SonicOne® products.

    Gross profit as a percentage of sales increased to 50.3% for the three months ended September 30, 2010 from 38.4% for the three months ended September 30, 2009.  Gross profit for medical device products increased to 54.7% for the three months ended September 30, 2010 from 45.4% for the three m
    '/>"/>

    SOURCE Misonix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Misonix Schedules Fourth Quarter and Fiscal Year 2009 Financial Results Conference Call; October 1, 2009 at 4:30 p.m. Eastern
    2. Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results
    3. Misonix, Inc. Announces the Sale of Sonora Medical Systems for $8 Million
    4. Misonix Announces New Distribution Agreement for United Kingdom and Republic of Ireland
    5. Misonix Announces New Distribution Agreement for Mexico
    6. Misonix Schedules First Quarter 2010 Financial Results Conference Call; November 16, 2009 at 4:30 p.m. Eastern
    7. Misonix Announces New Distribution Agreement for Saudi Arabia and Other Middle Eastern Countries
    8. Misonix Announces New Distribution Agreement for Peru
    9. Misonix Announces New Distribution Agreement For The United Arab Emirates (UAE)
    10. Misonix Announces New Distribution Agreement for Argentina
    11. Misonix Announces New Distribution Agreement for Kingdom of Saudi Arabia
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/17/2014)... , October 17, 2014 Investor-Edge ... Inc. (NASDAQ: ARNA ), NPS Pharmaceuticals Inc. ... XOMA ), Momenta Pharmaceuticals Inc. (NASDAQ: ... Free research on these five companies can be accessed ... on Thursday, October 16, 2014, ended on a mixed ...
    (Date:10/17/2014)... Wash. , Oct. 17, 2014  Talyst, a ... the 2014 LeadingAge Annual Meeting in Nashville, ... InSite System, the market leading solution for onsite, remote ... long term care facilities to safely and securely dispense ... time to first dose, helps ensure that the correct ...
    (Date:10/17/2014)... , Oct. 17, 2014   InnFocus, Inc ., reported ... the United States for up to 3 years ... Summit in Chicago . The ... of the annual meeting of the American Academy of ... treated approximately 150 glaucoma patients in 6 countries by early ...
    Breaking Medicine Technology:Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5Talyst Exhibits at LeadingAge Annual Meeting 2InnFocus Featured at the Ophthalmology Innovation Summit In Chicago 2
    ... PHILADELPHIA and LONDON , June 28 ... portfolio of drugs, whilst the proportion of total sales from newer drugs ... Factbook complied by CMR International, a Thomson Reuters business. , ... The new edition of the R&D Factbook ...
    ... Fla. , June 26 Data ... that linagliptin achieved statistically significant and sustained reductions ... (HbA1c),(1-4) fasting plasma glucose (FPG)(1-4) and postprandial glucose ... dipeptidyl peptidase 4 (DPP-4) inhibitor as an oral ...
    Cached Medicine Technology:Global Pharmaceutical R&D Productivity Declining According to Thomson Reuters, CMR International 2Global Pharmaceutical R&D Productivity Declining According to Thomson Reuters, CMR International 3Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes 2Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes 3Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes 4Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes 5Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes 6Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes 7Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes 8
    (Date:10/19/2014)... been working in the garment industry for decades, LunaDress’ dress ... James, one of the company’s top designers, many ladies like ... that add beauty to them. Chiffon floor length outfits are ... new selection of 2014 long prom dresses. , As ... available in over 20 popular designs. The company intends to ...
    (Date:10/19/2014)... 20, 2014 Recently, Fancyflyingfox.com, an innovative ... clothes, has announced its latest designs of 2014 ... the new elegant outfits are offered with big discounts, ... order before October 30 can enjoy this special offer. ... marketing strategies, it has become one of the leading ...
    (Date:10/19/2014)... NC (PRWEB) October 19, 2014 ... building program has just been released to the ... the online body building and fitness community. The ... attention of DietsAndFitnessGuides.com's Vin Delmonico prompting an investigative ... experience of hitting what is commonly known as ...
    (Date:10/19/2014)... Oct. 19, 2014 (HealthDay News) -- New stem cell-based ... lead to new treatments, a new study suggests. ... human intestinal tissue in a lab dish. They then ... for studying intestinal disorders, according to the researchers. ... diseases and conditions that can cause intestinal failure, from ...
    (Date:10/19/2014)... – The U.S. Government has initiated a major ... by 2025. However, a workgroup of nearly 40 ... in the U.S. Government,s National Plan to Address ... in scale, and adequately funded in order to ... by the workgroup to enlarge and strengthen the ...
    Breaking Medicine News(10 mins):Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Visual Impact Frequency Training Review: Rusty Moore's Latest Fitness Guide Released 2Health News:Scientists Grow, Implant Human Intestinal Tissue in Mice 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 3Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 4Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 5Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 6
    ... published insight into the biology of many kinds of less-aggressive ... wide array of possibilities for new therapies, according to scientists ... (UCSF). In paper published online Dec. 15 in the ... a genetic mutation leads to an abnormal metabolic process in ...
    ... happy holiday thought, but an important one: The number of ... surges by 33 percent on New Year,s Day. The suspected ... by sociologist David Phillips of the University of California, San ... on New Year,s is published in the journal Addiction ...
    ... Reporter , WEDNESDAY, Dec. 15 (HealthDay News) -- In a rare ... AIDS no longer has any detectable HIV cells in his blood ... But experts were quick to caution that the case ... As it turns out, the donor for that transplant ...
    ... HealthDay Reporter , WEDNESDAY, Dec. 15 (HealthDay News) -- Making ... diagnosis is not only unnecessary but may make it less likely ... a new study finds. Researchers reviewed records from the New ... who had been declared brain dead. All of the people had ...
    ... ICELAND, 15 December 2010 Scientists from deCODE genetics ... Spain and Romania today report the discovery of a ... human genome (SNPs) that impact individual baseline levels of ... is the most commonly used screening tool for the ...
    ... The recently identified TRIM24 protein plays an active role ... and, potentially, into breast cancer. Reporting in the ... at The University of Texas MD Anderson Cancer Center ... toward active expression. This expression, in turn, sets the ...
    Cached Medicine News:Health News:Insight offers new angle of attack on variety of brain tumors 2Health News:Insight offers new angle of attack on variety of brain tumors 3Health News:SIDS spikes on New Year's Day 2Health News:Docs Claim Transplant Cured Man of HIV, But Experts Urge Caution 2Health News:Docs Claim Transplant Cured Man of HIV, But Experts Urge Caution 3Health News:Second Brain Death Exam Unnecessary, Study Finds 2Health News:Second Brain Death Exam Unnecessary, Study Finds 3Health News:deCODE discovers genetic markers that improve the power of PSA testing for detecting prostate cancer 2Health News:Protein disables p53, drives breast cells toward cancer transition 2Health News:Protein disables p53, drives breast cells toward cancer transition 3
    Anti-PR3 EIA Auto-Immune Markers 013-PR3-96 Proteinase...
    ... For the quantitative determination of ... ,Patients with atopic allergic diseases such ... fever have been shown to exhibit ... blood. IgE is also known as ...
    ... growth factor 1 (IGF-1) is a polypeptide of ... of a number of related insulin-like growth factors ... 50% sequence homology with proinsulin and has a ... peptide is growth hormone (GH) dependent to a ...
    ...
    Medicine Products: